DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will be issuing its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $4.23 on Tuesday. DiaMedica Therapeutics has a 1 year low of $2.12 and a 1 year high of $4.95. The company has a market capitalization of $180.83 million, a P/E ratio of -7.98 and a beta of 1.46. The company has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $3.54.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DMAC. Oppenheimer restated an “outperform” rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, August 16th. HC Wainwright initiated coverage on DiaMedica Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $7.00 price target on the stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.